The O-6-methylguanine-DNA methyltransferase (MGMT) is a critical defence ag
ainst alkylation-induced mutagenesis and carcinogenesis, More than a 20-fol
d interindividual difference in the MGMT activity is known to exist among h
uman cultured fibroblasts. We previously reported three allelic variants of
the human MGMT gene, namely V1, V2, and V3, Both V1 and V2 carry amino aci
d substitutions, Leu(84)Phe and Trp(65)Cys, respectively, while V3 has a si
lent mutation. In order to reveal the pharmacogenetic and ecogenetic signif
icance of polymorphism in the human MGMT gene, we investigated the in-vivo
characteristics of V1 and V2 methyltransferase enzyme. Escherichia coil str
ain KT233 (ogt(-), ada(-)) and mer(-) HeLa MR cells carrying a V1 sequence
exhibited almost the same level of sensitivity against N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), as did those with a wild-type sequence. The level
of methyltransferase protein in those cells was essentially the same as for
the wild-type and V1 samples. On the other hand, E. coli and human cells e
xpressing V2 cDNA showed a significantly reduced level of survival, In thes
e cells, V2 protein was hardly detected, even though mRNA was produced norm
ally. An in-vitro translation experiment revealed that the V2 sequence had
the potential to produce methyltransferase protein, as did the wild-type an
d V1 sequences. There was also evidence for a small amount of V2 protein be
ing produced but rapidly degraded, thus implying that the V2 molecule is un
stable in vivo. Using purified recombinant proteins, we estimated the kinet
ic values of wild-type and variant form of enzymes, which would support the
se views. From these results, we concluded that the wildtype and V1 protein
have similar enzymatic and physicochemical properties, while V2 protein is
considered to be unstable and rare. Pharmacogenetics 10:59-66 (C) 2000 Lip
pincott Williams & Wilkins.